Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes
AssigneeJapanese Foundation for Cancer Research
InventorsKengo Takeuchi, Kana Sakamoto, Ryohei Katayama, Seiji Sakata
Life of this patent
Estimating the term…
Abstract
The diagnostic markers that provide novel diagnostic criteria to blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been searched, and the presence of immunoblastoid cytomorphology, 8q24 rearrangement, and MYC expression were established as novel markers for subtyping BPDCN. It has been further found that the inhibitors which directly or indirectly inhibit the expression, functions, or signaling pathways of MYC, such as BET bromodomain-selective inhibitors or aurora kinase inhibitors, are effective in MYC-positive BPDCN, and HDAC inhibitors or BCL2 family protein inhibitors are effective as therapeutic drugs for BPDCN.
Claims4
A method of treatment for a human patient having blastic plasmacytoid dendritic cell neoplasm (BPDCN), the method comprising:
- obtaining a biopsy sample from the patient;
- detecting a 8q24 rearrangement in the sample, the 8q24 rearrangement comprising one of the following:
- t(6;8)(p21;q24);
- t(8,9)(q24;q34);
- t(6,8)(p12;q24);
- and t(8;22)(q24;q11.2);
- classifying the BPDCN patient into a BPDCN subtype that has a 8q24 rearrangement;
- and
- administering a treatment to the patient that has a 8q24 rearrangement, wherein the treatment includes administering one or more bromodomain and extra terminal (BET) bromodomain-selective inhibitors or an aurora kinase inhibitor.
Dependencies are inferred from the claim text.